Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE: Radiotherapy + Immunotherapy vs Chemotherapy in NSCLC
NCT07603856Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Dec 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Chicago. Primary endpoint: Progression-free survival at 48 months. Planned start Dec 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07603856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603856.